Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.

Despite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.

Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.

Hypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

NCT01325740

Fragile X Syndrome

SUSPENDED PHASE2

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

NCT00788073

Fragile X Syndrome

COMPLETED PHASE2

"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)

NCT01855971

Fragile X Syndrome

COMPLETED PHASE2

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

NCT03569631

Fragile X Syndrome FXS Fra(X) Syndrome

COMPLETED PHASE2

A Trial of Metformin in Individuals With Fragile X Syndrome

NCT03479476

Fragile X Syndrome Fragile X Mental Retardation Syndrome Mental Retardation, X Linked +7 more

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.
* Design: Pilot clinical trial, Phase II , 6-month randomized, double-blind placebo-controlled one-way crossover clinical trial, with two treatment periods of 12 weeks duration.
* Setting: IMABIS Foundation. Carlos Haya Hospital, Malaga.
* Subjects: Children aged 5-11 years (infants) and 12-18 years (adolescents) diagnosed with Fragile X syndrome.
* Intervention: 30 participants randomly assigned, to receive antioxidant vitamins C (ascorbic acid) and vitamin E (d-alpha-tocopherol) once a day or placebo for 12 weeks double-blind. In Study Period 2, all participants receive (open) active treatment. Outcome measures: improvement in plasma antioxidant levels, oxidative stress (indicated by glutathione status, thiobarbituric acid reacting substances (TBARS) and carbonyl content of proteins) and HPA axis response. Behavioral problems will be studied using "Developmental behavior checklist" and "Teacher's and Parent´s Questionnaire, C. Keith Conners", also learning improvement will be analyzed using "Wechsler Intelligence Scale for children" at 0, 3, 6 months during the trial and 3 months after completing the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fragile X Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ascorbic Acid and alpha-tocopherol

Two daily doses of the combination of antioxidants, administered at breakfast and dinner

Group Type EXPERIMENTAL

Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)

Intervention Type DIETARY_SUPPLEMENT

* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)
* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks

Placebo

Two daily doses of placebo, administered at breakfast and dinner

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Two daily dose of placebo, administered at breakfast and dinner for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)

* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)
* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Placebo

Two daily dose of placebo, administered at breakfast and dinner for 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Molecular genetics diagnosis of the syndrome (number of CGG repeats in the FMR1 gene over 200).
* Presenting characteristic symptoms of fragile X syndrome.
* Patients older than 6 years and younger that 19 years.
* Signed informed consent by parents and/or legal tutor prior to enrolment in the trial.
* Both parents and patients must commit to participate for the duration of the 30 week trial.

Exclusion Criteria

* The study excludes individuals with other neurological disorders not linked to the syndrome.
* Patients that have had serious medical problems in the previous 12 months.
* Are taking more than 100mg of vitamin E or vitamin C daily for the past 4 months.
* Have physical problems, mental or sensory impairments that preclude the assessment of effectiveness.
* Hypersensitivity to any component of the preparation.

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No